Advertisement

Chemotherapy and Radiotherapy in Gynaecological Cancer

  • Paul Symonds
Chapter

Abstract

Chemotherapy kills cancer largely by damaging tumour DNA and preventing replication. It can be used for cure, symptom control, to reduce risks of recurrence or to make other cancer treatments such as radiotherapy more effective. Radiotherapy is the use of ionising radiation to kill cancers. It is usually given in multiple treatments (fractions) to minimise damage to normal tissue. Both modalities are widely used in the treatment of gynaecological cancers. This chapter deals with litigation related to their usage.

Keywords

Chemotherapy Radiotherapy Gynaecological cancer Complications Prognosis 

References

  1. 1.
    Bissett D, Lamont DW, Nwabineli NJ, et al. The treatment of stage I carcinoma of the cervix in the west of Scotland 1980-1987. Br J Obstet Gynaecol. 1994;101:615–20.CrossRefPubMedGoogle Scholar
  2. 2.
    Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery on high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Vale CL, Tierney JF, Davidson SE, et al. Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologist’s audit. Clin Oncol. 2010;22:590–601.CrossRefGoogle Scholar
  5. 5.
    Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with Stage 1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Postoperative radiation therapy in endometrial carcinoma. Lancet. 2000;355:1404–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority randomised trial. Lancet. 2010;375:816–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG. 2007;114:1313–20.CrossRefPubMedGoogle Scholar
  8. 8.
    Hogberg T. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Clin Oncol. 2008;20:463–9.CrossRefGoogle Scholar
  9. 9.
    The International Collaborative Ovarian Neoplasm (ICON) group. Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505–15.CrossRefGoogle Scholar
  10. 10.
    The ICON and AGO collaborators. Paclitaxel plus platinum based chemotherapy versus conventional platinum based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–106.CrossRefGoogle Scholar
  11. 11.
    Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulval cancer: a phase II study of the Gynaecologic Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:79–85.CrossRefPubMedGoogle Scholar
  13. 13.
    Homesley HD, Bundy BN, Sedlis A, et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynaecol. 1986;68(6):733–40.Google Scholar
  14. 14.
    Kunos C, Simpkins F, Gibbons H, et al. Radiation therapy compared with pelvic node resection for node positive vulvar cancer: a randomized controlled trial. Obstet Gynecol. 2009;114(3):537–46.CrossRefPubMedGoogle Scholar
  15. 15.
    Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst. 2015;107(3):dju426.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Harland S. Moving on after a serious untoward incident. Trends Urol Mens Health. 2013;4:33–6.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of LeicesterLeicesterUK

Personalised recommendations